Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

Eli Lilly and Company (NYSE:LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Ricks said Eli Lilly had yet to begin what the company calls "demand-stimulating activities," or advertising and promoting, for Zepbound. The drugmaker will start those efforts in November, he said.